KeyBank National Association
PCVX icon

KeyBank National Association’s Vaxcyte PCVX Stock Holding History

KeyBank National Association’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,908
Closed -$218K – 1186
2024
Q3 		$218K Sell
1,908
-2,712
-59% -$244K ﹤0.01% 1069
2024
Q2 		$349K Buy
4,620
+418
+10% +$28.5K ﹤0.01% 887
2024
Q1 		$287K Sell
4,202
-134
-3% -$9.28K ﹤0.01% 944
2023
Q4 		$272K Sell
4,336
-229
-5% -$11.9K ﹤0.01% 952
2023
Q3 		$233K Buy
4,565
+522
+13% +$25.8K ﹤0.01% 936
2023
Q2 		$202K Buy
+4,043
New +$192K ﹤0.01% 1013

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KeyBank National Association's PCVX Position: Q4 2024 in Review

KeyBank National Association sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 1,908 shares — an estimated $218K sold.

KeyBank National Association first reported a position in PCVX in Q2 2023 and held it in 6 quarters. The position peaked at $349K in Q2 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • KeyBank National Association reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • KeyBank National Association sold 1,908 Vaxcyte shares in Q4 2024, an estimated $218K.
  • KeyBank National Association first reported a position in Vaxcyte in Q2 2023 and held it in 6 quarters.
  • KeyBank National Association's Vaxcyte position peaked at $349K in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on KeyBank National Association's 13F filing for Q4 2024, filed 6 Feb 2025.